OTC: GCTK · Industrial Applications and Services · 11 alerts · CIK 1506983
Share price
$0.1900Close, Nov 16
Market cap
$2.01M
Shares outstanding
10.58MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Glucotrack, Inc. filings on SEC EDGAR ↗
Glucotrack received notice from a Nasdaq Hearings Panel that its securities will be delisted after failing to maintain a $1.00 minimum bid price through the required exception period. Trading on Nasdaq will be suspended on October 30, 2026, and the company plans to transition its common stock to the OTC Markets Group (OTCID).
Glucotrack, Inc. implemented a 1-for-2 reverse stock split of its common stock effective October 23, 2026. The split reduced the number of outstanding shares from approximately 2.37 million to 1.18 million to satisfy Nasdaq listing requirements. The company's common stock began trading on a split-adjusted basis on October 26, 2026.
Glucotrack, Inc. announced a 1-for-2 reverse stock split of its common stock effective October 26, 2026, to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split will reduce the outstanding share count from approximately 2.37 million to 1.18 million shares. Separately, the company raised $2.0 million in gross proceeds through the issuance of senior secured convertible promissory notes and warrants.
Glucotrack entered into a waiver agreement with warrant holders to terminate certain restrictive covenants and exercise price adjustment provisions from a July 2026 purchase agreement. In consideration for these waivers, the company agreed to issue new warrants to purchase 406,198 shares of common stock at an exercise price of $7.50 per share.
Glucotrack, Inc. filed an amended 8-K to provide updated pro forma financial statements regarding its completed acquisition of Lokahi Therapeutics Inc. The update specifically reflects the impact of a 1-for-15 reverse stock split that became effective on August 28, 2026. Following the merger, Lokahi became a direct wholly owned subsidiary of Glucotrack.
Glucotrack Debt Financing Update with September Investors
Glucotrack, Inc. entered into amendments for its senior secured convertible promissory notes and various common stock purchase warrants issued in July, August, and September 2026. The amendments primarily remove downward adjustments to the Floor Price and mandate that make-whole payments be satisfied only in cash, while the company also confirmed the full repayment of its July Bridge Notes.
Glucotrack, Inc. entered into a securities purchase agreement for a registered direct offering of 169,388 shares of common stock and pre-funded warrants for 1,350,220 shares, raising approximately $3.1 million in gross proceeds. The offering was priced at $2.04 per share (or $2.039 per pre-funded warrant) and is intended to fund debt repayment and general working capital.
Glucotrack CEO Erik Emerson provided a strategic update following the company's recent business combination with Lōkahi Therapeutics. The update highlights the development of LT-100 for osteoarthritis knee pain, including the submission of a clinical protocol for regulatory review and plans for a study evaluating subcutaneous injection efficacy.
Paul V. Goode resigned from the Board of Directors of Glucotrack, Inc. effective September 14, 2026. Mr. Goode cited a potential conflict of interest between the company and its subsidiary regarding the implementation of duties and rights under a prior merger agreement with Lokahi Therapeutics, Inc.